Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh
In low-resource settings, IGlar can be a cost-effective alternative to NPH, largely due to reduced nocturnal hypoglycemia, but the delivery device for the insulin has a major impact on the costs and cost-effectiveness comparisons.
Authors
- Olugbenga Akinola (ORCID: https://orcid.org/0000-0002-3514-072X)
- Alana Nicole Garvin
- Angela Foulds
- Christina M. Lalama (ORCID: https://orcid.org/0000-0001-6711-481X)
- Margaret L. Prust (ORCID: https://orcid.org/0000-0001-6595-9237)
- Renatus Fabiano Nyarubamba (ORCID: https://orcid.org/0000-0003-1620-1328)
- Edna Majaliwa (ORCID: https://orcid.org/0000-0002-3880-6320)
- Sylvia Kehlenbrink (ORCID: https://orcid.org/0000-0003-1828-2643)
- Graham D. Ogle (ORCID: https://orcid.org/0000-0002-2022-0866)
- Ajmina Hasan Flabe (ORCID: https://orcid.org/0000-0001-8675-7490)
- Bedowra Zabeen
- Kaushik Ramaiya
- Jing Luo
Institutions
- Brigham and Women's Hospital (US)
- University of Pittsburgh (US)
- Diabetes Australia (AU)
- Aga Khan Hospital Dar es Salaam (TZ)
- International Diabetes Federation (BE)
- Clinton Health Access Initiative (US)
- Tanzania Public health Association (TZ)
- Muhimbili National Hospital (TZ)
- Diabetes UK (GB)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1371/journal.pone.0333652
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00